Form 10-Q · Quarterly report
Avery Dennison 10-Q, filed Nov 3, 2026
- Filed
- CIK
- 0000008818
- Accession no.
- 0000008818-26-000166
Summary
Avery Dennison reported third-quarter 2026 net sales of $2.33 billion, up 5% from $2.22 billion a year earlier, with organic sales up 4%, and said net income for the first nine months of 2026 rose to about $542 million from about $522 million. The company recorded $40.4 million in restructuring charges, net of reversals, over the first nine months tied to the reduction of roughly 690 positions, and its adjusted free cash flow rose to $715.8 million from $404.5 million.
Key points
- Third-quarter 2026 net sales were $2,331.5 million versus $2,215.5 million in the same period of 2025, with income before taxes of $241.2 million versus $234.8 million.
- Nine-month 2026 net sales change was 8%, or 5% excluding currency effects and acquisitions, with organic sales change of 4%.
- Net cash provided by operating activities was $843.5 million in the first nine months of 2026 versus $504.6 million a year earlier.
- Avery Dennison said it expects a favorable full-year foreign currency translation impact, higher interest expense, a full-year effective tax rate in the high-twenty percent range, and incremental restructuring savings net of transition costs.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Management’s Discussion and Analysis of Financial Condition and Results of Operations, or MD&A, should be read in conjunction with the accompanying unaudited Condensed Consolidated Financial Statements and related notes thereto. NON-GAAP FINANCIAL MEASURES We report our financial results in conformity with accounting principles generally accepted in the United States of America, or GAAP, and also communicate with investors using certain non-GAAP financial measures. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.